Secondary T-lymphoblastic leukemia in a patient with hairy cell leukemia following cladribine therapy: report of an extremely rare case and review of the literature-Reference-Cited by-同舟云学术

Secondary T-lymphoblastic leukemia in a patient with hairy cell leukemia following cladribine therapy: report of an extremely rare case and review of the literature

Published:2012-04 Issue:4 Volume:53 Page:736-738
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Setoodeh Reza,Zhang Ling

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.628722

Reference14 articles.

1. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

2. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience

3. Second Cancer Incidence and Cause-Specific Mortality Among 3104 Patients With Hairy Cell Leukemia: A Population-Based Study

4. Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With Cladribine

5. Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review;Cancers;2024-04-11

2. Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma;Hematological Oncology;2015-11-18

3. Second hematologic malignancies in hairy cell leukemia: report of two patients with dynamic mutations in the BRAF gene;Leukemia & Lymphoma;2014-08-20

4. Hairy cell leukemia and multiple myeloma: Two distinct entities or a single two-phase disease;Acta Haematologica Polonica;2014-01

5. First reports of serious adverse drug reactions in recent weeks;Drugs & Therapy Perspectives;2012-12